Global Osteoporosis Drugs Market Research Report - Forecast to 2027

Global Osteoporosis Drugs Market Information, by drug class (Bisphosphonates, Calcitonins, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone (PTH) and Others), by route of administration (oral, injectable and others) and by gender (male and female) - Forecast to 2027

ID: MRFR/Pharma/1841-HCR | February 2021 | Region: Global | 84 pages

Please note that the assessment period of report has been updated from 2013- 2022 to 2020-2027. Cordially fill Sample form for updated data.

Market Synopsis of Global Osteoporosis Drugs Market: Market Scenario: Osteoporosis is weakening of bones due to lower bone mass resulting in and micro-architectural deterioration of bone tissue and subsequent higher risk of a broken fracture. It generally occurs at an advanced age and women are more susceptible to it than males by about three to four folds. WHO estimates that around 1.66 million hip fractures occur each year worldwide due to osteoporosis. According to national osteoporosis foundation about 54 million Americans suffer from osteoporosis.


The disease also has a genetic bias in that it Caucasians are more affected than Asians. The disease prevalence is lowest in African population.


The market driving factors were identified to be rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc.


The market restraints are loss of patents of block busters, greater penetration of generics and fragmentation of market, poor efficacy and side effects of present therapies, non-life threatening nature and poor symptoms of osteoporosis etc.


Taking all the factors into consideration, we expect the global osteoporosis market which totaled ~ $10,855 million to reach 14,300 million by 2022, growing with a CAGR of 4.7%.


 


Study Objectives Global Osteoporosis Drugs Market:



  • To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global osteoporosis drugs market

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by drug class (bisphosphonates, calcitonins, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others), by route of administration (oral, injectable and others) and by gender (male, female and children).

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.


Global Osteoporosis Drugs Market, by Route of Administration, 2015 (%):


Osteoporosis Drugs Market, by Route of Administration, 2015 (%) 


Key Players for Global Osteoporosis Drugs Market: Some of the key players in this market are: Eli Lilly and Company, Merck & Co., Novartis International AG, Amgen Inc., F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd. and others. Segments: Global osteoporosis drugs market has been segmented on the basis of drug class which comprises bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of gender the market is segmented into male and female. Intended Audience:



  • Osteoporosis Drugs Manufacturers

  • Osteoporosis Drugs Suppliers

  • Private Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Government Research Laboratories

  • Contract Manufacturing Organizations


Regional Analysis of Global Osteoporosis Drugs Market: Globally America is the largest market for osteoporosis drugs. Europe is the second-largest market for osteoporosis drugs. The developed regions are expected to hold their market leadership in the near future but with falling market share due to rise of Asia Pacific region which is expected to be fastest growing region in osteoporosis drugs market. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global osteoporosis market.


The report for Global Osteoporosis Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 14,300 Million
  CAGR   2013-2022: 4.7%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Class, Route of Administration, Gender
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Eli Lilly and Company, Merck & Co., Novartis International AG, Amgen Inc., F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd
  Key Market Opportunities   Research and developments
  Key Market Drivers

  • Rise in the geriatric population
  • Increased screening
  • Drug induced osteoporosis
  • Increased awareness and focus towards female health
  • Rising prevalence of diseases


  • Frequently Asked Questions (FAQ) :


    The global osteoporosis drugs market is expected to thrive at a CAGR of 4.7% from 2015 to 2022.

    The global osteoporosis drugs market size can inflate to USD 14,300 million by 2022.

    The global osteoporosis drugs market stood at USD 10,855 million in 2014.

    Drug induced osteoporosis, rise in the numbers of the geriatric populace, and focus towards female health are major drivers of the global osteoporosis drugs market.

    Patent expiry of blockbuster drugs, large penetration of generics, and side-effects of current treatments are major challenges of the global osteoporosis drugs market.

    The Americas can dominate the global osteoporosis drugs market due to large prevalence of osteoporosis among the elderly.

    Pfizer Inc., Merck & Co., Amgen Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Eli Lilly and Company, and Novartis International AG are the major players of the global osteoporosis drugs market.

    1 Introduction

    1.1 Definition

    1.2 Scope of Study

    1.3 Research Objective

    1.4 Assumptions & Limitations

    1.5 Market Structure

    2 Research Methodology

    2.1 Research Process

    2.2 Primary Research

    2.3 Secondary Research

    3 Market Dynamics

    3.1 Drivers

    3.2 Restraints

    3.3 Opportunities

    3.4 Challenges

    3.5 Macroeconomic Indicators

    4 Market Factor Analysis

    4.1 Porter’s five forces model

    4.1.1 Bargaining Power of suppliers

    4.1.2 Bargaining Power of Customer

    4.1.3 Intensity of Competitor’s

    4.1.4 Threat of New Entrants

    5 Global Osteoporosis Drugs market, by Drug Class

    5.1 Introduction

    5.2 Bisphosphonates

    5.3 Calcitonins

    5.4 Selective Estrogen Receptor Modulators (SERMs)

    5.5 Parathyroid Hormone (PTH

    5.6 Others

    6 Global Osteoporosis Drugs Market, By Route of Administration

    6.1 Introduction

    6.2 Oral

    6.3 Injectable

    6.4 Others

    7 Global Osteoporosis Drugs Market, By Gender

    7.1 Introduction

    7.2 Male

    7.3 Female

    8 Global Osteoporosis Drugs market, by Regions

    8.1 Introduction

    8.1.1 Americas

    8.1.1.1 North America

    8.1.1.2 South America

    8.1.2 Europe

    8.1.2.1 Germany

    8.1.2.2 France

    8.1.2.3 UK

    8.1.2.4 Italy

    8.1.2.5 Spain

    8.1.2.6 Rest of Europe

    8.1.3 Asia Pacific

    8.1.3.1 Japan

    8.1.3.2 China

    8.1.3.3 India

    8.1.3.4 Republic of Korea

    8.1.3.5 Rest of Asia Pacific

    8.1.4 Middle East & Africa

    9 Company Landscape

    9.1 Introduction

    9.1.1 Mergers Acquisitions

    9.1.2 Collaborations

    9.1.3 Release/New Product Launches

    9.1.4 Other (Expansion, Updates, Partnership)

    10 Company Profile

    10.1 Eli Lilly and Company

    10.1.1 Company Overview

    10.1.2 Product/Business Segment Overview

    10.1.3 Financials

    10.1.4 Key Developments

    10.1.5 SWOT Analysis

    10.2 Merck & Co.

    10.2.1 Overview

    10.2.2 Product/Business Segment Overview

    10.2.3 Financials

    10.2.4 Key Developments

    10.2.5 SWOT Analysis

    10.3 Novartis International AG

    10.3.1 Overview

    10.3.2 Product/Business Segment Overview

    10.3.3 Financials

    10.3.4 Key Developments

    10.3.5 SWOT Analysis

    10.4 Amgen Inc.

    10.4.1 Overview

    10.4.2 Product/Business Segment Overview

    10.4.3 Financials

    10.4.4 Key Developments

    10.4.5 SWOT Analysis

    10.5 F. Hoffmann La Roche Ltd.

    10.5.1 Overview

    10.5.2 Product/Business Segment Overview

    10.5.3 Financials

    10.5.4 Key Developments

    10.5.5 SWOT Analysis

    10.6 Pfizer Inc.

    10.6.1 Overview

    10.6.2 Product/Business Segment Overview

    10.6.3 Financials

    10.6.4 Key Developments

    10.6.5 SWOT Analysis

    10.7 Novo Nordisk

    10.7.1 Overview

    10.7.2 Product/Business Segment Overview

    10.7.3 Financials

    10.7.4 Key Developments

    10.7.5 SWOT Analysis

    10.7 Teva Pharmaceutical Industries Ltd.

    10.7.1 Overview

    10.7.2 Product/Business Segment Overview

    10.7.3 Financials

    10.7.4 Key Developments

    10.7.5 SWOT Analysis

    10.8 Others

    10.8.1 Overview

    10.8.2 Product/Business Segment Overview

    10.8.3 Financials

    10.8.4 Key Developments

    10.8.5 SWOT Analysis

    11 Others

    12 Appendix

    List of Tables

    TABLE 1 GLOBAL OSTEOPOROSIS DRUGS MARKET, 2020-2027 (USD MILLION)

    TABLE 2 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

    TABLE 3 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

    TABLE 4 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY GENDER, 2020-2027 (USD MILLION)

    TABLE 5 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

    List of Figures

    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 PORTERS FIVE FORCES MODEL

    FIGURE 3 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY DRUG CLASS

    FIGURE 4 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

    FIGURE 5 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY GENDER

    FIGURE 6 GLOBAL OSTEOPOROSIS DRUGS MARKET, BY REGION

    FIGURE 7 GLOBAL OSTEOPOROSIS DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)